Why All Honey Is Not Equal: A Researcher's Guide
Dr. Ferhat Öztürk's program has screened hundreds of honey samples for bioactivity — and the central finding is simple: honeys differ. What “variety” means in the lab, why Manuka is the reference standard, and what comparative research actually shows.
Ask Dr. Ferhat Öztürk's research program a simple question — is this honey antibacterial? — and the answer is never a yes or no. It is a measurement. His teams have screened hundreds of honey samples for bioactivity, and the central finding a non-scientist should grasp is disarmingly simple: all honey is not equal. This guide explains what “variety” means in the lab, why one famous honey became the reference standard, and what comparative research actually shows — and doesn't.
What “variety” means in the lab
In the supermarket, variety means a label: clover, wildflower, orange blossom. In Öztürk's lab, variety means measurable differences in composition — and composition correlates with bioactivity. His 2025 Antibiotics paper (lead author; DOI: 10.3390/antibiotics14090887) tested honey compounds and royal jelly against the periodontitis pathogen Aggregatibacter actinomycetemcomitans JP2 and found that hydrogen peroxide and flavonoid content correlated with antibacterial strength: the more of these compounds, the lower the concentration needed to inhibit the pathogen. Different honeys carry different chemistry — so different honeys perform differently.
- Texas screening: in 2022 his team set out to test some 60 Texas honey samples — 35 from San Antonio — against pathogens including MRSA, with the stated goal of elevating U.S. honeys to the level of New Zealand's Manuka (San Antonio Report, September 2022).
- The ambition on record: a KSAT 12 segment the same year described the hunt for U.S. honeys that could “not only compete with, but outperform those of current medical grade honeys.”
- Scale: student scientists in the HONEY Pathway program have analyzed more than 500 honey samples for bioactivity (Spectrum News, November 2025); his professional site describes 600+ samples across multiple U.S. regions.
- Clinical context: his 2024 systematic review of honey for burn-wound treatment covered 38 studies from 2013–2024 — faster recovery, reduced infection, improved scar formation — evidence built variety by variety, study by study.
Manuka and the reference standard
Every field has a reference point, and in medical-grade honey it is New Zealand's Manuka — the honey against which others are measured. Öztürk's stated goal was never to dismiss it but to match it: find American honeys with comparable bioactivity, measured the same way. The 2025 Journal of Wound Care consensus paper he co-authored (DOI: 10.12968/jowc.2024.0206) makes the deeper point: “medical-grade” is defined by criteria — organic production, gamma sterilization, clinical safety benchmarks, physicochemical measurements — not by origin. A variety earns the title; no variety owns it.
Checklist
What “variety” means scientifically
- Floral origin: which blossoms the bees worked — the starting chemistry.
- Geography and season: region and harvest conditions shape composition.
- Composition: hydrogen peroxide, flavonoids, and other bioactive compounds — the measurable part.
- Processing and storage: heat, filtration, and age change what the lab finds.
- Measured bioactivity, not label claims: antibacterial activity documented in assays, the way Öztürk's program screens sample by sample.
ghmap.io covers the field's agenda: companies, products, regulation, and market access. For market access, “variety” stops being a tasting note and becomes documentation: traceable sourcing, batch-to-batch consistency, and measured criteria a distributor or regulator can verify. The lab's variety question and the market's quality question are the same question, asked in different rooms.
Frequently asked questions
Q: Do different honeys really differ in antibacterial activity?
A: Research says the chemistry differs and the activity follows it. Öztürk's 2025 Antibiotics paper correlated hydrogen peroxide and flavonoid content with antibacterial strength against a periodontitis pathogen — composition, measured; activity, measured.
Q: What did the Texas honey screening test?
A: About 60 Texas samples (35 from San Antonio) tested against pathogens including MRSA, with the goal of finding U.S. honeys rivaling Manuka — reported by the San Antonio Report in September 2022.
Q: Why is Manuka the reference standard?
A: It is the established medical-grade benchmark the field measures against. Öztürk's stated aim was to elevate U.S. honeys to that level through comparative bioactivity testing — not to replace the standard, but to meet it.
Q: Does “raw” or “local” mean medical-grade?
A: No. Per the 2025 consensus standards, medical-grade requires gamma sterilization, traceable organic sourcing, clinical safety benchmarks, and measured physicochemical criteria — a label cannot substitute for the process.
Q: How many samples has the research program analyzed?
A: More than 500 honey samples analyzed by student scientists (reported November 2025); his professional site describes 600+ samples studied across multiple U.S. regions.
If you are bringing a wound-care or natural-product innovation toward a first market — first evidence package, first distributor, first hospital pilot — a ghmap.io market-entry brief maps your stages. See the link below.
Next step
Bringing a wound-care or natural-product innovation toward a first market? A ghmap.io market-entry brief maps your stages — pathway, documentation, channel, and payment. Planning conversations, not approval services and not outcome guarantees.
Get a market-entry brief
